Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $28.83

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $28.83.

Several research analysts have recently commented on IMNM shares. Stephens started coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Finally, Piper Sandler decreased their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th.

Immunome Stock Performance

Immunome stock opened at $11.02 on Friday. The stock has a 50-day simple moving average of $12.07 and a 200 day simple moving average of $13.25. The stock has a market capitalization of $687.84 million, a P/E ratio of -1.36 and a beta of 1.83. Immunome has a 52 week low of $8.97 and a 52 week high of $30.96.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall purchased 66,057 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the purchase, the chief executive officer now owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert Lechleider purchased 15,805 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the transaction, the insider now owns 15,805 shares of the company’s stock, valued at $149,831.40. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 102,862 shares of company stock valued at $978,045. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new stake in shares of Immunome in the second quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Immunome during the 2nd quarter worth $97,000. Arizona State Retirement System raised its holdings in Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after acquiring an additional 918 shares in the last quarter. AQR Capital Management LLC raised its holdings in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after acquiring an additional 4,129 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Immunome during the 3rd quarter valued at $219,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.